Discovery

Development

Testing

Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish

Antibody Drug Conjugates

Technologies & Platforms
WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA
Oct 23, 2014

SHANGHAI, Oct. 23, 2014 — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients.

“We commend TaiMed’s great progress in advancing this important life-saving therapy,” said Dr. Ge Li, Chairman and CEO of WuXi. “This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China.”

BACK